Combination chemotherapy of hepatocellular cancer. Comparison of adriamycin + VM 26 + 5-fluorouracil with mAMSA + VM 26 + 5-fluorouracil.
Forty-seven patients with hepatocellular cancer were treated in a randomised trial comparing adriamycin + VM 26 + 5-Fluorouracil (5-FU) to mAMSA + VM 26 + 5-FU. Thirteen patients had a partial response to treatment (28%) and another 6 (13%) showed disease stabilisation. There were no significant differences in the response rates between the two treatment regimens. Patients who responded to treatment showed significant prolongation of survival (48 weeks) when compared to non-responders (5 weeks).
D000328:Adult; D000677:Amsacrine / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000401:mortality; D002986:Clinical Trials as Topic; D004317:Doxorubicin / Q000008:administration & dosage*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage*; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D011897:Random Allocation; D013713:Teniposide / Q000008:administration & dosage*; D013997:Time Factors
D000677:Amsacrine; D004317:Doxorubicin; D013713:Teniposide; D011034:Podophyllotoxin; D005472:Fluorouracil